American multinational pharma company; key cancer, autoimmune and cardiovascular medicines
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
EY has warned the UK economy could slip into recession if Hormuz remains closed, while a reopening could keep growth resilient at 0.9% in 2026 and 1.2% in 2027. The outlook shifts with oil prices easing and talks of a potential AstraZeneca–BMS merger, set against a backdrop of manufacturing activity data and a stretched timetable for a takeover.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.